Trial reportDiabetes care2018
Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial.
Trial report in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 76 citations in OpenAlex.
- A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial.Journal of diabetes and its complications · 2022Trial
- Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE.BMJ open diabetes research & care · 2021Trial
- A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment.Diabetes care · 2021Trial
- Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes.The Journal of clinical endocrinology and metabolism · 2020Trial
- Hemoglobin glycation index correlates with the prognoses of critically ill patients with hyperlipidemia: a retrospective cohort study from the MIMIC-IV database.BMC endocrine disorders · 2026Article
- Associations of Hemoglobin Glycation Index with Glucose Variability and Time in Ranges in Patients with Type 2 Diabetes Undergoing Continuous Glucose Monitoring.International journal of medical sciences · 2026Article
- A dynamic weighted ensemble learning framework for cardiovascular risk prediction in type 2 diabetes: a comparative study with SHAP-based interpretability.Scientific reports · 2025Article
- Impact of hemoglobin glycation index on prognosis in critical patients with acute ischemic stroke: A retrospective cohort study using MIMIC-IV 2.2 database.Scientific reports · 2025Article
- The relationship between hemoglobin glycation index and all-cause mortality in ill critically patients with heart failure: a retrospective study in MIMIC-IV database.BMC cardiovascular disorders · 2025Article
- Generalized framework for identifying meaningful heterogenous treatment effects in observational studies: A parametric data-adaptive G-computation approach.Statistical methods in medical research · 2025Article
- Machine Learning-based Prognostic Model for Brain Metastasis Patients: Insights from Blood Test Analysis.Journal of Cancer · 2025Article
- Association between hemoglobin glycation index and the risk of cardiovascular disease in early-stage cardiovascular-kidney-metabolic syndrome: evidence from the China health and retirement longitudinal study.Frontiers in endocrinology · 2025Article
- Relationship between hemoglobin glycation index and risk of hypoglycemia in type 2 diabetes with time-in-range in target.World journal of diabetes · 2024Article
- Association of haemoglobin glycation index with all-cause and cardiovascular disease mortality in diabetic kidney disease: a cohort study.Diabetology & metabolic syndrome · 2024Article
- Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post-hoc machine learning analysis of ACCORD trial data.Diabetes, obesity & metabolism · 2024Article
- Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- The Role of Inflammation and Psycho-Behavioral Factors as Mediators Between Acculturation and Time to Incident Dementia Among Older Mexican Americans.Journal of Alzheimer's disease : JAD · 2024Article
- Article
- Precision subclassification of type 2 diabetes: a systematic review.Communications medicine · 2023Article
- Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine.BMC medical informatics and decision making · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveIdentifying patients who may experience decreased or increased mortality risk from intensive glycemic therapy for type 2 diabetes remains an important clinical challenge. We sought to identify characteristics of patients at high cardiovascular risk with decreased or increased mortality risk from glycemic therapy for type 2 diabetes using new methods to identify complex combinations of treatment effect modifiers. RESEARCH DESIGN AND
methodsThe machine learning method of gradient forest analysis was applied to understand the variation in all-cause mortality within the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (
resultsThe analysis identified four groups defined by age, BMI, and HGI with varied risk for mortality under intensive glycemic therapy. The lowest risk group (HGI <0.44, BMI <30 kg/m
conclusionsAge, BMI, and HGI may help individualize prediction of the benefit and harm from intensive glycemic therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.